Our Aim
Vivasc Therapeutics is a pre-clinical cardiac drug development company. We are utilizing the proprietary Cardiac Targeting Peptide (CTP) platform technology to deliver oligonucleotides exclusively to cardiomyocytes in a non-invasive manner.
Vivasc’s lead compound is an intravenous injection of CTP conjugated to a micro-RNA to treat heart failure at the root cause molecular level.
We are actively seeking partners for this effort.